Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience

Autor: Anna Di Noto, Lucia Spano, Mattia Fleres, Gabriella Saura, Alessandro Scorsone, Vito Aiello, Vincenzo Provenzano, Davide Brancato, Francesca Provenzano
Rok vydání: 2017
Předmět:
Blood Glucose
Male
medicine.medical_specialty
Article Subject
endocrine system diseases
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
Type 2 diabetes
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Body Mass Index
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Glucosides
Internal medicine
Diabetes mellitus
medicine
Humans
Hypoglycemic Agents
030212 general & internal medicine
Dapagliflozin
Benzhydryl Compounds
Aged
Retrospective Studies
Glycated Hemoglobin
lcsh:RC648-665
business.industry
Type 2 Diabetes Mellitus
nutritional and metabolic diseases
Retrospective cohort study
Middle Aged
medicine.disease
Metformin
Treatment Outcome
chemistry
Diabetes Mellitus
Type 2
Observational study
Drug Therapy
Combination
Female
business
Body mass index
medicine.drug
Research Article
Zdroj: Journal of Diabetes Research
Journal of Diabetes Research, Vol 2018 (2018)
ISSN: 2314-6753
Popis: Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Results. Data on 66 patients were included. In both groups, HbA1c was significantly reduced at 6 and 12 months compared with baseline and significant reductions in HbA1c were observed at 12 months compared with 6 months. Over the 12-month treatment period, dapagliflozin significantly reduced BMI in both groups. No significant changes in lipid parameters were observed in either group and no detrimental effects on renal function were detected. Conclusions. Dapagliflozin is effective and safe in patients with T2D also receiving metformin. Glycemic control was already achieved with dapagliflozin + metformin, and add-on therapy was not associated with further improvements.
Databáze: OpenAIRE
Externí odkaz: